卡维地洛与普萘洛尔预防代偿期和失代偿期肝硬化患者失代偿及死亡的比较
多中心回顾性研究纳入540例肝硬化伴临床显著门脉高压患者,比较卡维地洛与经典非选择性β受体阻滞剂(普萘洛尔、纳多洛尔)的效果。调整后,卡维地洛显著降低代偿期患者首次失代偿风险(sHR 0.61,95%CI 0.41-0.92,p=0.019),并显著降低失代偿期患者进一步失代偿/死亡复合终点风险(sHR 0.57,95%CI 0.42-0.77,p<0.0001)。作者结论支持优先使用卡维地洛,但建议不广泛用于有循环功能障碍或复发性/难治性腹水征象的失代偿期患者。
要点
- 卡维地洛较经典非选择性β受体阻滞剂显著降低代偿期肝硬化首次失代偿风险(sHR 0.61)。
- 卡维地洛较经典非选择性β受体阻滞剂显著降低失代偿期肝硬化进一步失代偿/死亡复合终点风险(sHR 0.57)。
- 作者建议不将结果广泛外推至有循环功能障碍或复发性/难治性腹水的失代偿期患者。
核心结论
- 数据支持当前推荐优先使用卡维地洛预防肝硬化首次失代偿,并建议将推荐扩展至无复发性或难治性腹水的失代偿期肝硬化患者。
- 由于研究为回顾性且存在固有选择偏倚,作者建议不将 findings 广泛应用于有循环功能障碍征象或复发性/难治性腹水的失代偿期肝硬化患者。
研究设计与样本
- 多中心回顾性研究,纳入540例代偿期和失代偿期肝硬化伴临床显著门脉高压患者。
- 患者在接受静脉普萘洛尔急性血流动力学应答评估(HVPG较基线下降≥10%)后、食管静脉曲张出血一级预防前纳入。
- 代偿期256例(经典非选择性β受体阻滞剂111例,卡维地洛145例),失代偿期284例(经典非选择性β受体阻滞剂134例,卡维地洛150例)。
- 采用逆概率治疗加权在竞争风险框架下调整结局。
主要发现
- 代偿期患者中位随访36.3个月(IQR 16.9-61.0),失代偿期患者中位随访30.7个月(IQR 13.1-52.2)。
- 协变量平衡后,卡维地洛较经典非选择性β受体阻滞剂显著降低代偿期患者首次失代偿风险(sHR 0.61,95%CI 0.41-0.92,p=0.019)。
- 卡维地洛较经典非选择性β受体阻滞剂显著降低失代偿期患者进一步失代偿/死亡复合终点风险(sHR 0.57,95%CI 0.42-0.77,p<0.0001)。
- 176例代偿期(68.8%)和177例失代偿期(62.3%)患者接受了第二次HVPG检测。
- 急性无应答者中,卡维地洛组获得慢性血流动力学应答的可能性更高:代偿期11.1% vs 29.4%(p=0.422),失代偿期16.0% vs 43.6%(p=0.0247)。
临床怎么用
- 作者结论支持优先使用卡维地洛预防肝硬化首次失代偿,并建议将推荐扩展至无复发性或难治性腹水的失代偿期肝硬化患者。
- 作者建议不将研究结果广泛应用于有循环功能障碍征象或复发性/难治性腹水的失代偿期肝硬化患者。
局限性
- 研究为回顾性设计,存在固有选择偏倚。
- 作者建议不将 findings 广泛应用于有循环功能障碍征象或复发性/难治性腹水的失代偿期肝硬化患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Data on the effectiveness of classical non-selective beta-blockers (cNSBBs, i.e., propranolol and nadolol) vs. carvedilol in patients with cirrhosis are scarce. In the present study, we aimed to compare their potential for preventing decompensation and mortality in patients with compensated and decompensated cirrhosis. METHODS: We performed a multicenter retrospective study including patients with compensated and decompensated cirrhosis with clinically significant portal hypertension, undergoing measurement of hepatic venous pressure gradient (HVPG) to assess acute hemodynamic response to intravenous propranolol (i.e., HVPG decrease ≥10% from baseline value) prior to primary prophylaxis for variceal bleeding. Outcomes were adjusted using inverse probability of treatment weighting in a competitive risk framework. RESULTS: A total of 540 patients were included, 256 with compensated (cNSBBs n = 111; carvedilol n = 145) and 284 with decompensated (cNSBBs n = 134; carvedilol n = 150) cirrhosis. Median follow-up was 36.3 (IQR 16.9-61.0) and 30.7 (IQR 13.1-52.2) months, respectively. After covariate balancing, compared to cNSBBs, carvedilol significantly reduced the risk of a first decompensation in compensated patients (subdistribution hazard ratio 0.61; 95% CI 0.41-0.92; p = 0.019) and a combined endpoint of further decompensation/death in decompensated patients (subdistribution hazard ratio 0.57; 95% CI 0.42-0.77; p <0.0001). A second HVPG was conducted on 176 (68.8%, compensated) and 177 (62.3%, decompensated) patients. Acute non-responders, both compensated (11.1% vs. 29.4%; p = 0.422) and decompensated (16.0% vs. 43.6%: p = 0.0247) patients, showed a higher likelihood of achieving a chronic hemodynamic response with carvedilol. The safety profile of each type of NSBB was comparable in both cohorts. CONCLUSIONS: Our data endorse the current recommendation favoring the use of carvedilol for the prevention of a first decompensation of cirrhosis and suggest extending the recommendation to patients with decompensated cirrhosis without recurrent or refractory ascites. IMPACT AND IMPLICATIONS: This study addresses a gap in the comparative effectiveness of classical non-selective beta-blockers (e.g., propranolol and nadolol) vs. carvedilol in managing cirrhosis in both compensated and decompensated stages. Our results support the preferential use of carvedilol in both settings due to its superior efficacy in reducing first and further decompensation. However, owing to the retrospective nature of the study and inherent selection biases, we advise against broadly applying these findings to patients with decompensated cirrhosis who exhibit signs of circulatory dysfunction or recurrent/refractory ascites.
引用
- Fortea JI, Alvarado-Tapias E, Simbrunner B, et al. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol. 2024. PMID: 39701300. doi:10.1016/j.jhep.2024.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。